The relationship and mechanism of SNPs, AEs and PK in Chinese renal cell carcinoma patients treated with sunitinib

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-16008840

Enrollment

Unknown

Registered

2016-07-14

Start date

2016-07-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

All people:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and/or women with the aged than 18 years; 2. Evaluation of renal clear cell carcinoma; 3. ECOG physical status score 0, 1, or 2 points; 4. Understand and voluntarily signed written informed consent, willing and able to abide by all test requirements.

Exclusion criteria

Exclusion criteria: 1. Any clinical significance of gastrointestinal tract anomalies,due to be damaging to the study drug intake, transshipment or absorption; 2. Severe liver function damage (Child - Pugh, C); 3. Positive test for HIV, HCV, HBV - DNA = 103 copies/mL; 4. Patients with severe or uncontrollable bacteria, viruses or fungus infection; 5. any other factors which do not fit to participate in the test according to the researchers.

Design outcomes

Primary

Measure	Time frame
drug concentration in plasma;Single nucleotide polymorphisms;Adverse effect;	—

Countries

China

Contacts

Public ContactQu Hengyan

Affiliated Hospital of Military Medical Science Academy of the PLA of Chinese

quhymail@126.com+86 010-66947481

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026